semaglutide cardiovascular outcomes news today 2025 semaglutide has demonstrated reduced risk of major adverse cardiovascular events - tampa-tirzepatide semaglutide reduced the risk of major adverse cardiac events by 20 Semaglutide Cardiovascular Outcomes News Today: A 2025 Outlook

semaglutide-delaware-county The year 2025 is proving to be a landmark year for understanding the profound impact of semaglutide on cardiovascular health. Recent news and ongoing research are solidifying its role not just as a powerful tool for weight management and diabetes control, but as a significant factor in reducing the risk of major adverse cardiovascular events (MACE). This focus on cardiovascular outcomes is transforming metabolic medicine and offering new hope for individuals at high risk.

A cornerstone of this evolving understanding is the SELECT trial, a pivotal study that has demonstrated that semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity. Beyond the initial findings, further analyses consistently highlight semaglutide's proven ability to reduce the risk of cardiovascular events by 20-26%作者：B O’Shea—Semaglutideis proven to reduce the risk ofcardiovascularevents by 20-26 per cent,1 meaning fewer hospitalisations, heart attacks, stroke and .... This translates into tangible benefits, meaning fewer hospitalizations, heart attacks, strokes, and deaths. Notably, semaglutide reduced cardiovascular events independent of weight loss in adults with overweight or obesity, suggesting a multifaceted mechanism of action that extends beyond its metabolic effects.Cardiovascular outcomes of semaglutide and tirzepatide ...

The development of oral semaglutide, marketed as Rybelsus, has further expanded the accessibility and application of this revolutionary medication2025年9月18日—Ozempic®(once-weekly injectablesemaglutide) was associated with a 23% reduced risk of heart attack, stroke and death in people with type 2 .... News from 2025 indicates that oral semaglutide (Rybelsus) reduced the risk of major cardiovascular events like heart attack and stroke. The SOUL trial, a significant study in this area, revealed that oral semaglutide reduced the risk of a primary outcome event by 24% compared to placebo over a median follow-up of 3.4 years. In fact, the SOUL trial achieved its primary endpoint, demonstrating a 14% reduction in the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease (CKD), or both. Further findings from the SOUL trial highlight that oral semaglutide improved each of the composite measures, including death from cardiovascular causes, nonfatal stroke, and nonfatal myocardial infarction.18小时前—Several secondaryoutcomesalso favored orforglipron, including reductions in fasting glucose, triglycerides, total cholesterol, and systolic ... This trial also showed that oral semaglutide improved CV outcomes in patients with type 2 diabetes and known cardiovascular disease, and even demonstrated a 14% reduction in the risk of heart attack, stroke, and cardiovascular death.

The news is also abuzz with comparisons and evolving therapeutic strategies. Research is examining semaglutide versus tirzepatide in reducing major adverse cardiovascular events, with early indications suggesting that both semaglutide and tirzepatide reduced major adverse cardiovascular events. However, independent analyses are also emerging. For instance, a study in 2025 found that myocardial infarction occurred in 1.6% of patients with oral semaglutide versus 2.7% with sitagliptin, representing a notable risk reduction. This reinforces that semaglutide has demonstrated reduced risk of major adverse cardiovascular events.

Beyond the broader MACE, specific cardiovascular endpoints are also being positively impacted. The once-weekly injectable semaglutide, prominently known as Ozempic®, was associated with a 23% reduced risk of heart attack, stroke, and death in people with type 2 diabetes, according to reports from September 2025Semaglutide and cardiovascular outcomes by baseline .... Additional results from the REACH study demonstrate that once-weekly semaglutide was associated with a 25% risk reduction of heart attack, stroke. These findings are instrumental in understanding the comprehensive cardiovascular benefits of semaglutideNew head-to-head real-world study shows semaglutide ....

Importantly, the benefits of semaglutide are being observed across diverse patient populations. A particularly encouraging development is that semaglutide reduced the risk of major adverse cardiac events by 20% regardless of baseline obesity status according to previous analyses, and more recent data from trials in 2025 continue to underscore these significant reductions. Furthermore, semaglutide reduces the potential for major unfavorable outcomes without increasing the incidence of AKI, acute pancreatitis, highlighting its favorable safety profile in the context of cardiovascular risk reduction.

As we look towards the remainder of 2025, the scientific community is actively presenting and analyzing data that further solidifies semaglutide's role in promoting cardiovascular health.Novo Nordisk to present Wegovy and Ozempic data ... Presentations at major conferences, such as the American Heart Association (AHA) and the European Association for the Study of Diabetes (EASD), are continually shedding light on its efficacy and safetySOUL trial shows oral semaglutide has positive CV .... The ongoing exploration of semaglutide and its impact on cardiovascular outcomes is a testament to its transformative potential in managing chronic diseases and improving patient prognosesAt ADA 2025, the SOUL trial revealed that oral semaglutide .... The evidence is overwhelmingly pointing towards semaglutide as a key player in the future of cardiovascular risk management.